Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial

Kayo Horibe, Katsutaro Morino, Itsuko Miyazawa, Sachiko Tanaka‐Mizuno, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Tsuyoshi Yanagimachi, Masahiro Yoshimura, Ryuta Itoh, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Yukihiro Fujita, Satoshi Ugi, Hiroshi Maegawa